Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

Christoph D Spinner; Tim Kümmerle; Jochen Schneider; Christiane Cordes; Hans Heiken; Hans-Jürgen Stellbrink; Ivanka Krznaric; Stephan Scholten; Björn Jensen; Christoph Wyen; Marin Viehweger; Clara Lehmann; Martin Sprinzl; Albrecht Stoehr; Markus Bickel; Heiko Jessen; Wilfried Obst; Petra Spornraft-Ragaller; Pavel Khaykin; Eva Wolf; Christoph Boesecke; Christoph D Spinner; Björn Jensen; Thomas Lutz; Petra Spornraft-Ragaller; Stellbrink,; Martin Hower; Ulrich Bohr; Wilfried Obst; Ivanka Krznaric; Martin Sprinzl; Franz Audebert; Tim Kuemmerle; Stefan Scholten; Heribert Hillenbrand; Christiane Cordes; Heribert Knechten; Birger Kuhlmann; Heiko Jessen; Patrick Beck; Gerd Fätkenheuer; Hartwig H F Klinker; Juergen K Rockstroh; Stefan Esser; Christoph Stephan; Olaf Degen; Andreas Bellmunt-Zschäpe; Pavel Khaykin; Norbert Brockmeyer; Albrecht Stoehr

doi:10.1093/ofid/ofaa356

Publisher Website

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

Authors

Spinner, Christoph D¹
Kümmerle, Tim²
Schneider, Jochen¹
Cordes, Christiane²
Heiken, Hans²
Stellbrink, Hans-Jürgen³
Krznaric, Ivanka⁴
Scholten, Stephan⁵
Jensen, Björn⁶
Wyen, Christoph^{2, 7}
Viehweger, Marin²
Lehmann, Clara⁷
Sprinzl, Martin⁸
Stoehr, Albrecht⁹
Bickel, Markus¹⁰
Jessen, Heiko¹¹
Obst, Wilfried¹²
Spornraft-Ragaller, Petra¹³
Khaykin, Pavel¹⁴
Wolf, Eva¹⁵
Boesecke, Christoph¹⁶
Spinner, Christoph D
Jensen, Björn
Lutz, Thomas
Spornraft-Ragaller, Petra
Stellbrink,
Hower, Martin
Bohr, Ulrich
Obst, Wilfried
Krznaric, Ivanka
Sprinzl, Martin
Audebert, Franz
Kuemmerle, Tim
Scholten, Stefan
Hillenbrand, Heribert
Cordes, Christiane
Knechten, Heribert
Kuhlmann, Birger
Jessen, Heiko
Beck, Patrick
Fätkenheuer, Gerd
Klinker, Hartwig H F
Rockstroh, Juergen K
Esser, Stefan
Stephan, Christoph
Degen, Olaf
Bellmunt-Zschäpe, Andreas
Khaykin, Pavel
Brockmeyer, Norbert
Stoehr, Albrecht

And 30 more

¹ Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Germany , (Germany)
² Private Practice, Germany , (Germany)
³ ICH Study Center, Germany , (Germany)
⁴ Private Practice, Zentrum für Infektiologie Prenzlauer Berg, Germany , (Germany)
⁵ Private Practice, Hohenstaufenring, Germany , (Germany)
⁶ University Hospital Düsseldorf, Germany , (Germany)
⁷ Department of Internal Medicine I, University Hospital Cologne, Germany , (Germany)
⁸ Department of Medicine I, University Hospital Mainz, Germany , (Germany)
⁹ Private Practice, IfI Institute, Germany , (Germany)
¹⁰ Private Practice, Infektiologiukum, Germany , (Germany)
¹¹ Private Practice, Jessen2, Germany , (Germany)
¹² Department of Gastroenterology, University Hospital Magdeburg, Germany , (Germany)
¹³ University Hospital Dresden, Germany , (Germany)
¹⁴ Private Practice, MainFachArzt, Germany , (Germany)
¹⁵ MUC Research Clinical Research Organization (CRO), Germany , (Germany)
¹⁶ Bonn University Hospital, Germany , (Germany)

Type

Published Article

Journal

Open Forum Infectious Diseases

Publisher

Oxford University Press

Publication Date

Aug 13, 2020

Volume

7

Issue

9

Identifiers

DOI: 10.1093/ofid/ofaa356

PMID: 32965277

PMCID: PMC7491710

Source

PubMed Central

Keywords

License

Unknown

Abstract

The DUALIS phase-III study demonstrated non-inferiority of an effective and safe switch to dolutegravir combined with boosted darunavir (2DR) in suppressed people living with HIV as compared to continue 2 nucleoside reverse transcriptase inhibitors in combination with boosted darunavir (3DR).

Report this publication

Statistics

Seen <100 times